Thrombolytic treatment as first option in recurrent tricuspid prosthetic valve thrombosis and Ebstein's anomaly.
Ebstein's anomaly is the most frequent cause of congenital tricuspid regurgitation. The coexistence of a mechanical heart prosthesis in a low-pressure circuit and poor compliance in the anticoagulant therapy contributed decisively to the appearance of recurrent mechanical heart valve thrombosis in these patients. A 49 years old female patient is reported where thrombolytic therapy with recombinant Streptokinase (TT-rSK) was the first treatment choice in seven recurrent episodes of prosthetic valve thrombosis.
Cáceres-Lóriga
Fidel Manuel
FM
Institute of Cardiology and Cardiovascular Surgery, Havana, Cuba. caceresm@infomed.sld.cu
Pérez-López
Horacio
H
Santos-Gracia
Jose
J
Morlans-Hernández
Karel
K
Marrero-Mirayaga
Maria A
MA
D004437:Ebstein Anomaly / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D011859:Radiography; D055502:Secondary Prevention; D013927:Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000517:prevention & control; D014261:Tricuspid Valve / Q000002:abnormalities* / Q000000981:diagnostic imaging / Q000187:drug effects
D005343:Fibrinolytic Agents